DIN 02527391 — TABRECTA 150 MG
TABRECTA is a tablet of Capmatinib marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Capmatinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02527391
- Brand name
- TABRECTA
- Active ingredient
- Capmatinib
- Strength
- 150 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- MET receptor tyrosine kinase inhibitor (protein kinase inhibitor)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Capmatinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02527405 | TABRECTA | 200 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |